Current Report Filing (8-k)
November 20 2019 - 8:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 20, 2019
CANCER
GENETICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
201
Route 17 North 2nd Floor, Rutherford, New Jersey
|
|
07070
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (201) 528-9200
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
CGIX
|
|
The
Nasdaq Capital Market
|
Item
2.02. Results of Operations and Financial Condition.
On
November 20, 2019, Cancer Genetics, Inc. (the “Registrant”) issued a press release regarding financial results for
the fiscal quarter ended September 30, 2019. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated
by reference herein.
Forward-Looking
Statements
This
report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities
laws. Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,”
“plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites
of such words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and
unknown risks and uncertainties that exist in the Registrant’s operations and business environment, which may be beyond
the Registrant’s control, and which may cause actual results, performance or achievements to be materially different from
future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than
statements of historical fact are statements that could be forward- looking statements. For example, forward-looking statements
include, without limitation: statements regarding prospects for additional customers; market forecasts; projections of earnings,
revenues, synergies, accretion or other financial information; and plans, strategies and objectives of management for future operations.
The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in the Registrant’s
filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31,
2018 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. These risks could cause actual results to differ
materially from those expressed in any forward- looking statements made by, or on behalf of, the Registrant. Forward-looking statements
represent the judgment of management of the Registrant regarding future events. Although the Registrant believes that the expectations
reflected in such forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance
that such expectations will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation
to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information,
future events or otherwise.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
As
described above, the following exhibits are furnished as part of this report:
Exhibit 99.1 — Press release, dated November 20, 2019.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CANCER
GENETICS, INC.
|
|
|
|
|
By:
|
/s/
M. Glenn Miles
|
|
Name:
|
M.
Glenn Miles
|
|
Title:
|
Chief
Financial Officer
|
|
|
|
Date:
November 20, 2019
|
|
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Sep 2023 to Sep 2024